Twist Bioscience Expects FY23 Revenue Guidance Of $241M-$242M, Compared To Previous Guidance Of $235M-$238M And Consensus Of $237.23M
Portfolio Pulse from Benzinga Newsdesk
Twist Bioscience has updated its FY23 revenue guidance to $241M-$242M, up from the previous guidance of $235M-$238M and above the consensus of $237.23M.
August 04, 2023 | 3:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Twist Bioscience's updated FY23 revenue guidance is higher than previous estimates and consensus, indicating potential growth.
Twist Bioscience's updated revenue guidance for FY23 is higher than both its previous guidance and the consensus estimate. This suggests that the company expects stronger performance and growth, which could positively impact its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100